Trevena (TRVN) Earns Media Sentiment Rating of 0.08

News stories about Trevena (NASDAQ:TRVN) have trended somewhat positive on Saturday, Accern Sentiment reports. Accern identifies negative and positive press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Trevena earned a news impact score of 0.08 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 46.0182315762801 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

A number of equities analysts have recently weighed in on the company. Oppenheimer Holdings, Inc. reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Trevena in a research note on Monday, November 13th. HC Wainwright reaffirmed a “buy” rating and issued a $5.00 price objective on shares of Trevena in a research note on Wednesday, November 8th. Needham & Company LLC dropped their price objective on Trevena from $9.00 to $7.00 and set a “buy” rating for the company in a research note on Wednesday, November 8th. Zacks Investment Research lowered Trevena from a “buy” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, Barclays PLC lowered Trevena from an “overweight” rating to an “equal weight” rating and dropped their price objective for the stock from $15.00 to $2.50 in a research note on Monday, October 16th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and ten have given a buy rating to the company’s stock. Trevena currently has a consensus rating of “Buy” and an average price target of $8.75.

Trevena (NASDAQ TRVN) opened at $1.77 on Friday. Trevena has a one year low of $1.35 and a one year high of $8.00. The company has a debt-to-equity ratio of 0.38, a current ratio of 4.92 and a quick ratio of 4.92.

Trevena (NASDAQ:TRVN) last announced its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.27) EPS for the quarter, beating analysts’ consensus estimates of ($0.33) by $0.06. During the same period in the prior year, the business earned ($0.57) EPS. research analysts predict that Trevena will post -1.23 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Trevena (TRVN) Earns Media Sentiment Rating of 0.08” was first posted by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at

Trevena Company Profile

Trevena Inc is a biopharmaceutical company, which is engaged in developing various therapies. The Company is developing OLINVO, a u-receptor G protein pathway selective modulator (u-GPS) for the management of moderate-to-severe acute pain where intravenous (IV) administration is preferred. It is focused on commercializing it in the United States for use in acute care settings, such as hospitals and ambulatory surgery centers.

Insider Buying and Selling by Quarter for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena Inc. and related companies with's FREE daily email newsletter.

Latest News

Leave a Reply